| 史亚飞,韩晓菲,李磊,张仁亚,刘启龙.乳腺癌分子分型在新辅助化疗中的疗效预测[J].济宁医学院学报,2015,(5):327-330 |
| 乳腺癌分子分型在新辅助化疗中的疗效预测 |
| The role of breast cancer molecular subtypes in the prediction of neoadjuvant chemotherapy |
| 投稿时间：2015-07-11 |
| DOI：10.3969/j.issn.1000-9760.2015.05.007 |
| 中文关键词: 乳腺癌|分子分型|新辅助化疗|临床特征 |
| 英文关键词: Breast cancer|Molecular subtype|Neoadjuvant chemotherapy|Clinical feature |
| 基金项目:济宁市科技局课题(编号:2012jnwk02、2013jnwk77);山东省教育厅课题(编号:J13LK13) |
| 作者 | 单位 | | 史亚飞 | 济宁医学院附属医院, 山东济宁 272029 | | 韩晓菲 | 济宁市第四人民医院, 济宁 272000 | | 李磊 | 济宁医学院附属医院, 山东济宁 272029 | | 张仁亚 | 济宁医学院附属医院, 山东济宁 272029 | | 刘启龙 | 济宁医学院附属医院, 山东济宁 272029 |
|
| 摘要点击次数: 4876 |
| 全文下载次数: 893 |
| 中文摘要: |
| 目的 回顾性分析4种乳腺癌分子分型的临床特点,比较其在新辅助化疗方案中的疗效。方法 回顾性分析本院初治并接受新辅助化疗的乳腺癌患者172例的病历资料。根据免疫组织化学结果,将乳腺癌患者分为4种亚型:Luminal A型、Luminal B型、Her-2过表达型和basal-like型。对不同亚型患者的临床资料进行分析,比较4种亚型乳腺癌患者在新辅助化疗中的疗效。结果 172例乳腺癌患者中,Luminal A型47.1%,Luminal B型23.8%,Her-2过表达型11.6%,Basal-like型16.3%;4种亚型的病理完全缓解率分别为11.1%、12.2%、35.0%、42.9%。Basal-like型病理完全缓解率明显高于Luminal A亚型和Luminal B亚型(P=0.012)。结论 乳腺癌分子亚型可作为病理完全缓解的独立预测因子,为乳腺癌个体化治疗提供依据。 |
| 英文摘要: |
| Objective The clinical characteristics of 4 breast cancer subtypes were analyzed retrospectively and their therapeutic effects of neoadjuvant chemotherapy were compared.Methods 172 cases of patients with breast cancer treated with neoadjuvant chemotherapy were included in this retrospective study.Molecular subtypes were categorized as Luminal A subtype,Luminal B subtype,HER-2 overexpression subtype and basal-like subtype,based on the immunohistochemistry results.The clinical data were analyzed and therapeutic effects of neoadjuvant chemotherapy were compared in the 4 different types of breast cancer.Results Among all 172 cases,the proportion of Luminal A subtype was 47.1%,Luminal B subtype 23.8%,HER-2 overexpression subtype 11.6%,and basal-like subtype 16.3% respectively.The pathologic complete remission rates of the four subtypes were:11.1%,12.2%,35.0% and 42.9%.The pathologic complete remission rate of patients with basal-like subtype was significantly higher than those of the patients with Luminal A subtype and Luminal B subtype (P=0.012).Conclusion Four molecular subtypes of breast cancer could be the independent indicator of the pathologic complete remission and the basis for individualized treatment for breast cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
|
|
|
